Home-Based Monitoring of Visual Field

This policy addresses home‑based visual field monitoring using preferential hyperacuity perimetry devices (e.g., ForeseeHome/Notal Vision DMC) for daily self‑testing to detect metamorphopsia, scotomas, or early choroidal neovascularization in patients at risk for or with age‑related macular degeneration (early, intermediate, geographic atrophy/dry, and neovascular/wet AMD) and select maculopathies such as diabetic retinopathy. Coverage is subject to member benefit plan/contract rules, is intended for stabilized patients, relies on limited evidence (primarily the single HOME trial), may be considered experimental/investigational for some indications, and this policy is designated inactive for current claims adjudication.

"Early AMD: absent visual impairment with presence of medium-sized drusen on retinal exam."

Sign up to see full coverage criteria, indications, and limitations.